May 21, 2018
Celgene has suffered a series of damaging stumbles over the last year, culminating last month with the exit of chief operating officer Scott Smith. In a quieter apparent departure, business development head George Golumbeski left the company in April as well. Golumbeski’s last day at..
Novartis CEO Vas Narasimhan conceded to investors today that the company does not yet have a good fix on how to make sure its Sandoz unit is a leader in the coming years. In Europe, where biosimilars and branded generics are popular, Sandoz is doing..
TapImmune is planning to merge with T-cell therapy startup Marker Therapeutics. The agreement will give TapImmune control of adoptive T-cell therapies designed to provide more durable responses than CAR-Ts and other genetically engineered treatments. Marker, a Baylor College of Medicine spinout, is based on technology..
Illlumina said Tuesday that it has acquired data analysis firm Edico Genome. Edico markets its DRAGEN platform, which uses field programmable gate array technology in combination with proprietary software algorithms to reduce data footprint and enable faster speeds. Users can run DRAGEN on site, in..
A year after taking the helm at Fierce 15 winner and cancer startup Aravive Biologics, former Astellas executive Stephen Eck, M.D., Ph.D., has jumped ship to Immatics US as its new chief medical officer. Eck, formerly VP and global head of oncology medical sciences at..
When Zymeworks and Daiichi Sankyo initially teamed up on bispecific antibodies in 2016, they kept the financial details under wraps. Now, the pair is entering a new license agreement that could potentially be worth $484.7 million. Under the original deal, Zymeworks licensed its Azymetric and..
Pharma watchers waited with bated breath for Friday’s drug pricing speech from President Donald Trump—who famously said the industry is “getting away with murder.” But the speech lacked surprises that could have negatively affected the industry, according to experts, and one analyst called it “very,..
ATyr Pharma is laying off 30% of its staff and otherwise cutting its costs in response to lackluster data. The biotech made the cuts after preclinical data on its anticancer antibodies suggested they lack the required efficacy. San Diego, California-based aTyr made ORCA its third..
Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that helps body’s immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market. Lilly’s offer of $50 per..
Betting heavily on a less-regulated CMO market, a Chinese company intends to build a massive biologics plant over the next several years to tap into what is predicts will be the country’s rapid move to cell-based drugs. In a public filing (PDF), China’s Shandong Sinobioway..